YarcData Aligns With Selventa to Help Pharmaceutical Companies Deliver Personalized Medicine

YarcData Aligns With Selventa to Help Pharmaceutical Companies Deliver Personalized Medicine

PLEASANTON, CA - YarcData, a Cray (NASDAQ: CRAY) company committed to providing a big data solutions for real-time data discovery, today announced a collaborative effort with Selventa, a leading provider of systems diagnostics for personalized medicine. Selventa will have access to YarcData's big data analytics appliance, Urika®, to help pharmaceutical organizations better target drugs, condense the time needed for new drug discoveries and accelerate market delivery.

"With 50 percent of drugs ineffective or worse, there is an immediate opportunity to better match treatments to individuals based on their biomarker profiles. Using this insight, pharmaceutical companies can create a larger number of targeted products that optimally benefit patients," said Dave de Graaf, President and CEO, Selventa.

"Big data and the intellectual properties derived from it have an immense potential to drive personalized medicine. This, in turn, will lead to an increase in knowledge and our requirements for scalable, flexible solutions that can deliver results in a fraction of the time than the traditional databases. In searching for a graph database solution, nothing compared to YarcData's ability to pull all the data into one platform and one memory space to achieve the real-time speed and scalability," Dr. Graaf concluded.

The YarcData Urika platform is a purpose-built, real-time appliance for automated data discovery that provides graph-optimized hardware and a graph database optimized for the underlying hardware enabling applications to interact with the appliance. Although it can be provisioned and managed by IT as any other Linux server, Urika is a highly scalable, real-time accelerated data discovery platform that augments existing systems, bringing data silos together to support ad hoc queries, pattern-based searches, inferencing and deduction. Because graph databases are more flexible than traditional systems, value can be extracted almost immediately, without waiting for months to build the ontology and load all of the data.

"Selventa's solution running on Urika will help pharmaceutical companies do what they have been trying to do on their own build databases that enable new drug discoveries and speed time to market," said Dave Anstey, Global Segment Leader for Life Sciences at YarcData. "We are seeing customers dramatically shorten their hypothesis validation cycle."

The combined YarcData and Selventa solution will provide the opportunity for pharmaceutical companies to explore data discoveries across disease areas. Traditional databases are usually partitioned by disease area in order to limit the size of the database and make searching more manageable. Because data loaded into Urika does not need to be partitioned, the solution will enable analysis to be performed across larger or combined data sets, making it possible to find previously unknown relationships between genes and proteins, treatments and disease mechanisms, human and animal biology, diseased tissue and blood, as well as identification of biomarkers representative of predictive and prognostic indications.

About Selventa
Selventa is pioneering the development of Systems Diagnostics (SysDx™). This novel approach to diagnostic development harnesses a comprehensive range of complex, biological information (genomic, epigenomic, transcriptomic, proteomic, metabolomic, electronic medical records) to generate a clinically relevant dashboard that physicians, patients and researchers can use to make an optimal treatment decision or stratify patient populations.